For US Healthcare Professionals
Based on the prespecified statistical hierarchy in the pivotal phase 3 clinical trial, Patient Global Impression of Change (PGIC) and OFF time were not eligible for statistical significance; however, analysis was conducted and nominal P values are provided for descriptive purposes, but conclusions cannot be drawn.13
*P<0.001; the nominal P value was not statistically significant per the prespecified hierarchy.13
Percentage of responses to survey question: “How has the addition of study drug changed your Parkinson’s disease?”11
of patients who used on average at least 1 dose per day were still on INBRIJA after 1 year, according to real-world prescription data (N=2559)11
INBRIJA is indicated for intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD) treated with carbidopa/levodopa.
Please see the Full Prescribing Information.
Intermittent treatment of OFF episodes in patients with PD treated with CD/LD.
Contraindicated in patients taking or who have recently taken (within 2 weeks) nonselective monoamine oxidase (MAO) inhibitors (e.g., phenelzine and tranylcypromine) due to hypertension risk. Discontinue use of nonselective MAO inhibitors at least 2 weeks prior to initiating INBRIJA.